NTLAIntellia Therapeutics, Inc.
$11.21-55% 1Y
$11.21
$8.0452 weeks$27.98
Is the price fair?
What NTLA's price assumes
Intellia Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 26.4× revenue.
26.4
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 2.16
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 18.8
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 2.16
- EV / EBIToperating margin −712%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 18.8
- Market capitalisation140.1 million shares, counted Jul 31, 2026
- $1.57B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks